Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation-Reference-Cited by-同舟云学术

Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation

Published:2019-12-06 Issue:2 Volume:26 Page:216-228
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Karuppuchamy Thangaraj¹¹,Tyler Christopher J¹¹,Lundborg Luke R¹¹,Pérez-Jeldres Tamara²³,Kimball Abigail K⁴⁵,Clambey Eric T⁴⁵,Jedlicka Paul⁶,Rivera-Nieves Jesús¹⁷

Affiliation:

1. Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA

2. Universidad Católica de Chile, Santiago, Chile

3. Hospital San Borja Arriarán, Santiago, Chile

4. Department of Anesthesiology Aurora, Colorado, USA

5. Department of Pathology, Aurora, Colorado, USA

6. Department of Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA

7. Gastroenterology Section, San Diego VA Medical Center, La Jolla Village Drive, San Diego, California, USA

Abstract

Sphingosine-1-phosphate (S1P) receptor agonists are a promising therapeutic alternative to anti-integrin antibodies in inflammatory bowel disease. Here, we report that modulation of tissue S1P levels via inhibition of the S1P lyase might be an effective alternative, acting by interference with thymocyte maturation.

Funder

National Institutes of Health

BLRD VA

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/26/2/216/31717788/izz174.pdf

Reference50 articles.

1. Targeting leukocyte traffic: a new era for the treatment of inflammatory bowel disease;Rivera-Nieves;J Crohns Colitis.,2018

2. Natalizumab for active Crohn’s disease;Ghosh;N Engl J Med.,2003